[A26-52] Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2026
Project no.:
A26-52
Commission:
Commission awarded on 15.05.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma with Claudin (CLDN) 18.2-positive tumours
- Patients with PD-L1 expression ≥ 1 (CPS): added benefit not proven
- Patients with PD-L1 expression < 1 (CPS): hint of a minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-52
| Project no. | Title | Status |
|---|---|---|
| G24-32 | Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-negative) – Assessment in accordance with § 35a Social Code Book (SGB) V (1), Sentence 11 | Commission completed |